API | ofatumumab

ofatumumab (arzerra) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA Accelerated Approval ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
ofatumumab

More Chemistry

Pharmacology

Mechanisms of Action:
- B-lymphocyte antigen CD20 (Homo sapiens) ^UniProt
- B-lymphocyte antigen CD20 (Homo sapiens) ^UniProt
- B-lymphocyte antigen CD20 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$86.6318 - $6812.4000

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (93)

Research & Development (93)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (40)

Approved Indications (2)

Leukemia, Lymphocytic, Chronic, B-Cell

Multiple Sclerosis

Experimental Indications - Clinical Trial Phases 1-4 (40)

Agammaglobulinemia (Phase 2)

Arthritis, Rheumatoid (Phase 3)

Burkitt Lymphoma (Phase 2)

Endoscopy (Phase 2)

Fatigue (Phase 2)

Fever (Phase 2)

Gonorrhea (Phase 1)

Graft vs Host Disease (Phase 1/Phase 2)

Hodgkin Disease (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell ()

Leukemia, Lymphoid (Phase 1/Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)

Leukemia, Prolymphocytic (Phase 1/Phase 2)

Lymphadenopathy (Phase 2)

Lymphocytosis (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 4)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Melanoma (Phase 2)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Neoplasms ()

Nephrotic Syndrome (Phase 2)

Neuromyelitis Optica (Phase 1/Phase 2)

Paraproteinemias (Phase 2)

Pemphigus (Phase 3)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Squamous Intraepithelial Lesions (Phase 2)

Sweat (Phase 2)

Thrombocytopenia (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 128
# of Trial Organizations: 93

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue